Delivery of beta-blockers through an inhalation route
First Claim
1. A condensation aerosol for delivery of atenolol formed by heating a composition containing atenolol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of atenolol and less than 5 percent by weight of atenolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to aerosols containing of atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in inhalation therapy. In a method aspect of the present invention, of atenolol, pindolol, esmolol, propranolol, or metoprolol is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of atenolol, pindolol, esmolol, propranolol, or metoprolol, on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering of atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route is provided which comprises: a) a thin coating of an atenolol, pindolol, esmolol, propranolol, or metoprolol composition and b) a device for dispensing said thin coating as a condensation aerosol.
-
Citations
54 Claims
- 1. A condensation aerosol for delivery of atenolol formed by heating a composition containing atenolol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of atenolol and less than 5 percent by weight of atenolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 4. A condensation aerosol for delivery of pindolol formed by heating a composition containing pindolol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of pindolol and less than 5 percent by weight of pindolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 7. A condensation aerosol for delivery of esmolol formed by heating a composition containing esmolol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of esmolol and less than 5 percent by weight of esmolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 10. A condensation aerosol for delivery of propranolol formed by heating a composition containing propranolol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of propranolol and less than 5 percent by weight of propranolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 13. A condensation aerosol for delivery of metoprolol formed by heating a composition containing metoprolol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of metoprolol and less than 5 percent by weight of metoprolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
-
16. A method of forming an atenolol containing aerosol comprising:
-
(a) heating composition containing atenolol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of atenolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (17, 18, 42)
-
-
19. A method of forming a pindolol containing aerosol comprising:
-
(a) heating a composition containing pindolol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of pindolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (20, 21, 43)
-
-
22. A method of forming an esmolol containing aerosol comprising:
-
(a) heating a composition containing esmolol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of esmolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (23, 24, 44)
-
-
25. A method of forming a propranolol containing aerosol comprising:
-
(a) heating a composition containing propranolol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of propranolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (26, 27, 45)
-
-
28. A method of forming a metoprolol containing aerosol comprising:
-
(a) heating a composition containing metoprolol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of metoprolol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (29, 30, 46)
-
-
31. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of atenolol, pindolol, esmolol, propranolol, and metoprolol, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (32, 33, 47)
-
-
34. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of atenolol, pindolol, esmolol, propranolol, and metoprolol, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (35, 36, 48)
-
-
49. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of atenolol, pindolol, esmolol, propranolol, and metoprolol, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (50, 51, 52, 53, 54)
-
Specification